Core Viewpoint - Di'an Diagnostics has been awarded the "Brand Leading·Benchmark Enterprise" title at the 11th Excellent Brand Building Classic Case Evaluation, highlighting its success in brand construction within the healthcare industry [1] Group 1: Brand Development - The "Double Product Project" initiated by the Ministry of Industry and Information Technology in 2014 aims to strengthen brand development in China, promoting high-quality products and global competitiveness [1] - Di'an Diagnostics positions itself as a leader in "intelligent medical diagnostic solutions," utilizing "AI + data" to create a comprehensive health diagnostic industry chain [1] Group 2: Innovation and Services - The company actively explores service model innovations, leveraging big data and AI to support precise medical decision-making and public health management [2] - Di'an Diagnostics has launched over 10 data products on the Hangzhou Data Exchange platform, providing essential data support for precise diagnosis and scientific research [2] Group 3: Global Expansion - Di'an Biological, a subsidiary, has successfully promoted self-developed products in Europe, Southeast Asia, the Middle East, and Central Asia, obtaining over 70 registration certificates [2] - The company is gradually building a global medical diagnostic service network, enhancing the international influence of Chinese medical manufacturing [2] Group 4: Social Responsibility - Di'an Diagnostics has established a diversified public welfare support system, focusing on health initiatives, and has won the "Social Public Welfare Award" from the China Cancer Foundation for fourteen consecutive years [4] - The company is committed to environmental responsibility, contributing to national carbon peak and carbon neutrality goals through investments in green laboratory construction and data security governance [6]

Core Insights - The strategic partnership between Dian Diagnostics and Hangzhou Data Group aims to establish a trusted data space in Hangzhou, marking Dian Diagnostics as the only third-party medical diagnostics company among the initial collaborators [2][4] - Dian Diagnostics has launched 16 data products on the Hangzhou Data Exchange platform, including datasets for cervical cancer screening, infection system diseases, vitamin D, coenzyme Q10, and allergens [2][3] - The company has accumulated 20PB of medical testing data from over 22,000 medical institutions, covering various fields such as oncology, infections, chronic diseases, and maternal and child health [2][3] Data Processing and Application - The data handling process consists of four stages: data collection and generation, preprocessing and storage, analysis and mining, and application and monetization [3] - The partnership focuses on building data infrastructure for the medical diagnostics industry, creating high-quality datasets, and developing AI medical products [4] - Future plans include expanding the monetization of data assets through financial innovation tools and exploring the value realization of medical testing data across various sectors, including clinical diagnosis, public health decision-making, and personal health management [4]